Crossmark

How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?

Crossref DOI link: https://doi.org/10.1007/s00261-024-04194-y

Published Online: 2024-03-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Changwu

Huang, Peng

Wu, Fei

Xiao, Yuyao

Yang, Chun

Zeng, Mengsu
Funding

Funding for this research was provided by:

National Science Foundation of China (82171897)

Clinical Research Plan of SHDC (SHDC2020CR1029B)

Science and Technology Commission of Shanghai Municipality (23Y11907400)
License Information

Text and Data Mining valid from 2024-03-01

Version of Record valid from 2024-03-01
More Information

Article History

Received: 17 November 2023

Revised: 6 January 2024

Accepted: 12 January 2024

First Online: 1 March 2024

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Zhongshan Hospital, Fudan University.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below